指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症哮喘抗白介素5治疗失败标准:一项德尔菲共识研究

Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study.
指南 / 共识 · Ther Adv Respir Dis · 2021-01-01
一句话结论专家共识定义重症哮喘抗IL-5/IL-5R治疗失败标准:治疗6个月后急性发作频率或口服糖皮质激素剂量未降低≥25%,或出现急诊就诊/住院,应停药。

本研究采用5轮德尔菲法,邀请20名来自国家级重症哮喘专家中心、管理≥30例患者的呼吸科专家参与。经两轮声明生成头脑风暴后,专家在后续三轮按5点李克特量表对每条声明评分。阳性共识标准为≥80%专家同意且>50%强烈同意、<15%不同意。共识定义抗IL-5/IL-5R治疗失败为:治疗6个月后急性发作频率未降低≥25%,或口服糖皮质激素剂量未较初始剂量降低≥25%,或出现急诊就诊或住院;治疗失败应导致停药。部分应答者不推荐停药,除非存在另一治疗类别的替代方案,并应在多学科会诊中讨论。

要点

  • 治疗6个月后急性发作频率未降低≥25%,或口服糖皮质激素剂量未较初始剂量降低≥25%,或出现急诊就诊/住院,定义为抗IL-5/IL-5R治疗失败。
  • 治疗失败应导致停药。
  • 部分应答者不推荐停药,除非存在另一治疗类别的替代方案,并应在多学科会诊中讨论。
  • 所有专家同意应在共享决策中通过患者契约个体化预设治疗目标以定义有效性。
  • 共识标准针对重症哮喘患者抗IL-5/IL-5R治疗的反应评估与停药决策。

适用人群与场景

  • 重症哮喘患者,接受抗白介素5/白介素5受体(抗IL-5/IL-5R)治疗。

诊断标准与关键阈值

  • 治疗失败定义(满足以下任一):(1)急性发作频率未降低≥25%;(2)口服糖皮质激素剂量未较初始剂量降低≥25%;(3)治疗6个月后出现急诊就诊或住院。
  • 阳性共识标准:≥80%专家同意且>50%强烈同意、<15%不同意。

处置流程与药物剂量

  • 治疗失败应导致停药。
  • 部分应答者不推荐停药,除非存在另一治疗类别的替代方案,并应在多学科会诊中讨论。
  • 所有专家同意应在共享决策中通过患者契约个体化预设治疗目标以定义有效性。

研究设计与关键结果

  • 研究类型:德尔菲共识研究,5轮(2轮声明生成头脑风暴+3轮李克特量表评分)。
  • 参与专家:20名呼吸科专家,均来自国家级重症哮喘专家中心,管理≥30例患者。
  • 共识达成:所有专家同意治疗目标应个体化并通过患者契约共享决策。
  • 治疗失败定义达成共识:急性发作频率未降低≥25%,或口服糖皮质激素剂量未较初始剂量降低≥25%,或治疗6个月后出现急诊就诊或住院。
  • 治疗失败应导致停药达成共识;部分应答者不推荐停药(除非有另一治疗类别替代方案且多学科会诊讨论)达成共识。

证据类型、等级与局限

  • 证据类型:德尔菲专家共识。
  • 共识阈值:阳性共识为≥80%专家同意且>50%强烈同意、<15%不同意。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对接受抗IL-5/IL-5R治疗的重症哮喘患者,可在治疗6个月时依据急性发作频率、口服糖皮质激素剂量降低幅度及急诊就诊/住院情况评估治疗失败。
  • 符合失败标准者应停药;部分应答者不推荐停药,除非存在另一治疗类别的替代方案,并应在多学科会诊中讨论。
  • 治疗前可通过患者契约在共享决策中个体化预设治疗目标以定义有效性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Current practices for assessing response to anti-interleukin 5/R treatment in severe asthma patients are heterogeneous. The objective of this study was to achieve an expert consensus defining failure criteria for anti-interleukin 5/R treatment in severe asthma patients.

METHODS: Experts were invited to a 5-round Delphi exercise if they were pulmonologists managing ⩾30 patients at a nationally recognized severe asthma expert centre. Following two rounds of statement-generating brainstorming, the expert panel ranked each statement according to a 5-point Likert-type scale during three additional rounds. Positive consensus was considered achieved when ⩾80% of experts agreed with a statement with >50% strong agreement and <15% disagreement.

RESULTS: Twenty experts participated in the study. All experts agreed that predefined treatment goals defining effectiveness should be personalized during shared decision making via a patient contract. Treatment failure was defined as (1) absence of a reduction in exacerbation rates by ⩾25% or (2) absence of a reduction in oral corticosteroid therapy by ⩾25% of the initial dosage or (3) occurrence of emergency room visits or hospitalizations after 6 months of treatment. Treatment failure should result in discontinuation. For partial responders, treatment discontinuation was not recommended unless an alternative from another therapeutic class exists and should be discussed in a multidisciplinary consultation.

CONCLUSION: The present study provides objective criteria for anti IL5 or IL5R failure in severe asthma and suggests consensus based guidelines for prescription, evaluation and discontinuation decision-making.

来源:Ther Adv Respir Dis,查看原文。版权归原作者所有。

参考来源

  1. Mattei L, Suehs CM, Alagha K, et al. Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study. Ther Adv Respir Dis. 2021. PMID: 34629000. doi:10.1177/17534666211049735

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。